REFERENCES
1. Dewald CLA, Becker LS, Meine TC, et al. New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option. Clin Exp Metastasis 2023;40:95-104.
2. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. Diagnostik und therapie des hepatozellulären karzinoms und biliärer karzinome. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome/ [Last accessed on 13 Mar 2024].
3. Koch C, Franzke C, Bechstein WO, et al. Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center. Digestion 2020;101:458-65.
4. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60:1268-89.
5. Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89.
6. Vashist Y, Aigner K, Gailhofer S, Aigner KR. Therapeutic effect of regional chemotherapy in diffuse metastatic cholangiocarcinoma. Cancers 2022;14:3701.
7. Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
8. Gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel in treating patients with newly diagnosed advanced biliary tract cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT03768414 [Last accessed on 13 Mar 2024].
9. Lamarca A, Palmer DH, Wasan HS, et al. Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021;22:690-701.
10. Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F. A new option for the treatment of intrahepatic cholangiocarcinoma: percutaneous hepatic perfusion with CHEMOSAT delivery system. Cells 2021;10:70.
11. Horesh N, Bomze D, Lim C, Markel G, Meirson T, Azoulay D. Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect. Hepatobiliary Surg Nutr 2022;11:861-9.
12. Vogel A, Bridgewater J, Edeline J, et al. ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:127-40.
13. Edeline J, Lamarca A, McNamara MG, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treat Rev 2021;99:102258.
14. Corte AD, Di Gaeta E, Steidler S, De Cobelli F. Radiological imaging and non-surgical local treatments for cholangiocarcinoma. Hepatoma Res 2022;8:5.
15. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 2012;35:91-9.
16. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
17. Hughes MS, Zager J, Faries M, et al. Results of a randomized controlled multicenter phase iii trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 2016;23:1309-19.
18. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23:3465-74.
19. Kirstein MM, Marquardt S, Jedicke N, et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 2017;143:2113-21.
20. Schönfeld L, Hinrichs JB, Marquardt S, et al. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol 2020;146:3003-12.
21. Dewald CLA, Warnke MM, Brüning R, et al. Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience. Cancers 2021;14:118.
22. Brüning R, Tiede M, Schneider M, et al. Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan-long-term overall survival negatively correlates with tumor burden. Radiol Res Pract 2020;2020:5672048.
23. Karydis I, Gangi A, Wheater MJ, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol 2018;117:1170-8.
24. Artzner C, Mossakowski O, Hefferman G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 2019;19:31.
25. Dewald CLA, Meine TC, Winther HMB, et al. Chemosaturation percutaneous hepatic perfusion (CS-PHP) with melphalan: evaluation of 2D-perfusion angiography (2D-PA) for leakage detection of the venous double-balloon catheter. Cardiovasc Intervent Radiol 2019;42:1441-8.
26. Dewald CLA, Becker LS, Maschke SK, et al. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis 2020;37:683-92.
27. Vogel A, Gupta S, Zeile M, et al. Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther 2017;33:2122-38.
28. Struck MF, Kliem P, Ebel S, et al. Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. PLoS One 2021;16:e0254817.
29. Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 2014;109:434-9.
30. Wacker F, Dewald C. [Local and locoregional treatment of intrahepatic cholangiocarcinoma]. Radiologe 2022;62:247-52.
32. Meijer TS, Burgmans MC, Fiocco M, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the delcath systems' second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol 2019;42:841-52.
33. Veelken R, Maiwald B, Strocka S, et al. Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol 2022;45:218-22.
34. Marquardt S, Kirstein MM, Brüning R, et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019;29:1882-92.
